Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone.
Ten patients (8 female, 2 male) with systemic lupus erythematosus (SLE) were entered into an open trial with the anabolic steroid 19-nortestosterone (19-nor). Their clinical condition did not improve, nor were significant changes observed in the majority of laboratory data. However, overall the platelet count rose, and in patients with abnormal levels of T lymphocytes bearing receptors for IgG Fc treatment returned the values to normal. Despite this latter result, suppressor cell activity remained slightly below the normal range throughout the study period.
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009277:Nandrolone / Q000627:therapeutic use*; D010976:Platelet Count; D011961:Receptors, Fc / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D011961:Receptors, Fc; D009277:Nandrolone